
Olaparib is used to treat ovarian, fallopian tube, primary peritoneal, pancreatic, breast, and prostate cancer.
Taking Olaparib as instructed is crucial to ensuring your treatment is as effective as possible. Here are some key points to remember:
The following are common side effects experienced by approximately one-third of patients taking Olaparib. Please note that you may not experience these side effects.
Decreased White Blood Cells (WBCs) and Increased Risk of Infection
Management: A blood test will be done before starting a new cycle of Olaparib to monitor your WBCs, haemoglobin, platelet count, liver, and kidney function.
Infection precautions:
Contact our unit if you experience any signs of infection:
Low Haemoglobin (Anaemia)
When your haemoglobin is low, you may feel more tired or fatigued.
Management:
Contact our unit if you experience:
Low Platelet Count (Thrombocytopenia) and Increased Risk of Bleeding
Management:
Contact our unit if you have bleeding that won’t stop, such as:
Visit the ER immediately if you experience:
Kidney Function
Contact our unit if you experience signs of reduced kidney function, such as:
Olaparib can remain in your body for several days after you take it. Some of the drug may be present in your urine, stool, sweat, or vomit. To ensure safety for you and those around you, please follow these guidelines:
Compiled by: Karin Mouton
Registered Oncology Nurse
Disclaimer
This e-brochure has been auto-translated for your convenience. While machine translations are helpful, they may contain errors. Medinformer is actively working to have all translations reviewed by professional, mother-tongue language speakers, though this process will take time. For the most accurate information, please refer to the original English version. Medinformer and its partners cannot be held responsible for any inaccuracies that may result from the translation.
Thank you for your understanding.